Empagliflozin in Patients with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Trial of empagliflozin in a broad chronic kidney disease population.
Overview
CoChat Summary
TL;DR
Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.
Key findings
- The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
- All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
- There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
- Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).
Methods
- Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
- Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
- Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.
Limitations
- The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
- Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
- Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A prespecified subgroup analysis from a trial of the SGLT2 inhibitor dapagliflozin in patients with CKD and a urinary ACR of at least 200 mg/g, found that kidney benefits extended to patients without diabetes”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Conclusions
What the sources say
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Abstract (p. 1437) specifies a urinary albumin-to-creatinine ratio of 200–5000 mg/g. Figure 2 identifies diabetes status as a prespecified subgroup, and the Discussion states that kidney-protective effects extended to participants with chronic kidney disease without type 2 diabetes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Wheeler DC Stefansson BV Jongs N Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021 9 1 22 31 10.1016/S2213-8587(20)30369-7 33338413 source
- Supportedcites [13] Staplin N Roddick AJ Emberson J Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials EClinicalMedicine 2021 41 101163 10.1016/j.eclinm.2021.101163 34765951 PMC8571171 source
The Results (Eligible trial characteristics) identify DAPA-CKD as a dapagliflozin trial in patients with CKD and urinary ACR of 200–5000 mg/g. The Results (Relative effects of SGLT-2 inhibitors) report that the effect on kidney disease progression in the CKD trial appeared similar with and without diabetes; the References identify the underlying DAPA-CKD work as a prespecified analysis. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of SGLT2 inhibition on kidney disease progression or cardiovascular death seen in the present trial is quantitatively similar to that seen in two other large placebo-controlled trials in CKD populations.6,7”
§ Empagliflozin in Patients with Chronic Kidney Disease > Discussion
What the sources say
- Supportedcites [6] Perkovic V Jardine MJ Neal B Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260 source
The Methods identify CREDENCE as a placebo-controlled trial in patients with type 2 diabetes and albuminuric CKD. Table 2 reports a hazard ratio of 0.70 for its primary composite of kidney disease progression or renal or cardiovascular death. This supports the citation’s role as one of the two earlier CKD trials; the paper does not itself compare its result with EMPA-KIDNEY. (LLM, conf=0.88)
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Efficacy Outcomes table reports that DAPA-CKD was a placebo-controlled trial in patients with chronic kidney disease and found a lower risk of the kidney-progression or cardiovascular-death composite with dapagliflozin (hazard ratio, 0.61). The cited paper supplies one of the two trial results; the statement that its effect is quantitatively similar to EMPA-KIDNEY is the citing authors’ comparison, not a finding attributed to this paper alone. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or death from any cause (4.5% vs 5.1%)”
- Also stated in: § Primary and Secondary Outcomes · plain
“or on death from any cause (hazard ratio, 0.87; 95% CI 0.70 to 1.08; P=0.21)”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of serious adverse events were broadly similar in the two groups.”
- Also stated in: § Safety Outcomes and Adverse Events · hedged
“There was no apparent evidence that empagliflozin increased the incidence of serious adverse events overall, or in any particular MedDRA system organ class (Table S8).”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety Outcomes and Adverse Events · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003)”
- Also stated in: § Primary and Secondary Outcomes · plain
“there were significantly fewer first and subsequent hospitalizations from any cause in the empagliflozin group (24.8 versus 29.2 hospitalizations per 100 patient years: hazard ratio, 0.86; 95% CI 0.78 to 0.95, P=0.003)”
- Also stated in: § Discussion · plain
“Risk of hospitalization for any cause was also reduced by 14%.”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
17 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozintreated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have beneficial effects on slowing progression of CKD and CV outcomes in this population (139-141).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, SGLT2i have been studied specifically among patients with CKD with or without T2D in 3 completed primary kidney outcome trials (CREDENCE[15], DAPA-CKD[16], and EMPA-KIDNEY[17]), which showed benefit for both a significant reduction in the primary kidney outcomes and cardiovascular outcomes [18,19].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The DAPA-CKD and FIDELIO trials enrolled patients with eGFR ≥25 mL/min/1.73 m2 and the EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m2; results demonstrated that dapagliflozin, finerenone and empagliflozin are effective and safe in these patients, although safety data are lacking for initiating therapy below these thresholds [16,17,22].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“…kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors, 3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors, 6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone 8,9 all reduced the…”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“6,7 The CREDENCE trial of canagliflozin required all participants to have type 2 diabetes and a urinary ACR of at least 300 mg/g, and excluded patients with an eGFR of less than 30 ml per minute per 1.73 m 2 .”
InfluentialLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 3×
“…with an estimated GFR (eGFR) below 30 ml per minute per 1.73 m 2 or on how these benefits might vary among the wider range of patients with CKD. 7,12,13 This multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess…”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cited by
Items 901–1,000 of 2,656
Fujita, K. K., Ye, F., Collister, D., Klarenbach, S. W., Campbell, D. J. T., Chew, D. S., Quinn, A. E., Ronksley, P. E., & Lau, D. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15361 · Cited by 7
Speedtsberg, E. S., & Tepel, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1281107 · Cited by 9
Hu, Y., Bao, J., Gao, Z., Ye, L., & Wang, L. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s446904 · Cited by 10
“79 SGLT-2 inhibitors improve renal tissue viability by ameliorating oxidative damage through reduced glucose reabsorption.”
BackgroundDiabetic Kidney Disease in Post-Kidney Transplant Patients
Pham, N.-Y. T., Cruz, D., Marin, L. M., Ravender, R., & García, P. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030793 · Cited by 9
Is Tirzepatide the New Game Changer in Type 2 Diabetes?
Lisco, G., Disoteo, O., Geronimo, V. D., Tullio, A. D., Giagulli, V. A., Guastamacchia, E., Pergola, G. D., Jirillo, E., & Triggiani, V. (2024) · Endocrines · doi:10.3390/endocrines5010005 · Cited by 8
Shimizu, A., Tsuboi, N., Sasaki, T., et al. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.04.046 · Cited by 7
Ten tips on immunosuppression in primary membranous nephropathy
Trujillo, H., Caravaca‐Fontán, F., & Praga, M. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae129 · Cited by 7
“Two large randomized trials [DAPA-CKD ( NCT03036150) and EMPA-KIDNEY ( NCT03594110) ] found that dapagliflozin and empagliflozin decrease the risk of CKD progression by 32% regardless of the presence of diabetes [3 – 5 ].”
BackgroundKanaoka, T., Wakui, H., Yano, Y., Nagasu, H., Kanegae, H., Nangaku, M., Hirakawa, Y., Nakagawa, N., Wada, J., Tsuruya, K., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15611 · Cited by 9
Kim, H. A., Jang, H. N., Kong, S. H., Lee, Y., Choi, S. H., Cho, Y. M., Jang, H. C., & Oh, T. J. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1919 · Cited by 6
Fazzini, L., Ghirardi, A., Limonta, R., Calabrese, A., D’Elia, E., Canova, P. A., Fontana, A., Grosu, A., Iacovoni, A., Ferrari, P., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14913 · Cited by 6
Ezhumalai, B., Modi, R., Panchanatham, M., & Kaliyamoorthy, D. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.07.005 · Cited by 11
Advances in primary glomerulonephritis
Ellison, B., Cader, R., & Willcocks, L. C. (2024) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0044 · Cited by 8
Михайлович, М. Е., Reitblat, O. M., Vyalkina, Y. A., Airapetian, A. A., Lazareva, N. V., Ageev, F. T., Николаевна, Б. З., Николаевна, С. О., Prints, I. S., Жиров, И. В., et al. (2024) · Terapevticheskii arkhiv · doi:10.26442/00403660.2024.07.202781 · Cited by 7
Exploring SGLT-2 inhibitors and sarcopenia in FAERS: a post-marketing surveillance study
Kuai, Z., Ye, Y., Zhang, X., Gao, L., Tang, G., & Yuan, J. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2412234 · Cited by 7
Sakamoto, T., Miyamoto, H., Hashizume, J., Akamatsu, H., Akagi, T., Kodama, Y., Hamano, H., Zamami, Y., & Ohyama, K. (2024) · Clinical Drug Investigation · doi:10.1007/s40261-024-01394-8 · Cited by 7
Trends in type 2 diabetes medication use and guideline adherence in Belgian primary care (2019–2023)
Raat, W., Mamouris, P., Mathieu, C., Goderis, G., & Vaes, B. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.10.007 · Cited by 6
Nicola, L. D., Cupisti, A., D’Alessandro, C., Gesualdo, L., Santoro, D., & Bellizzi, V. (2024) · Journal of Nephrology · doi:10.1007/s40620-024-02135-y · Cited by 9
Recomendaciones preventivas vasculares. Actualización PAPPS 2024
Orozco‐Beltrán, D., Brotons-Cuixart, C., Banegas, J. R., Gil-Guillén, V. F., Cuenca, A. M. C., Martín-Rioboó, E., Jordá-Baldó, A., Vicuña, J., & Navarro-Pérez, J. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103123 · Cited by 13
Finerenone in the management of diabetes kidney disease
De, P., Khine, M. T., Frankel, A., Goldet, G., Banerjee, D., Montero, R., Chowdhury, T. A., Fogarty, D., Karalliedde, J. J., Mallik, R., et al. (2025) · BMC Nephrology · doi:10.1186/s12882-025-03985-9 · Cited by 12
Cheng, R. K.-H., Roberts, M. B., Bansal, N., Reding, K. W., Salahuddin, T., Mamas, M. A., LaMonte, M. J., Shadyab, A. H., Franceschini, N., Klein, L., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037051 · Cited by 11
“In particular, sodium-glucose cotransporter 2 inhibitors mitigate the decline in eGFR for individuals with CKD 25,26 and dapagli-flozin reduces the risk for HF hospitalization or death from cardiovascular causes in those with CKD. 26 The association of CKD with incident HF appears to be stronger in…”
Feng, Q., Wu, M., & Mai, Z. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1482918 · Cited by 13
Tangchitthavorngul, S., Lumlertgul, N., Peerapornratana, S., Mai, A. T., Hasan, M. S., Loh, C. T. I., Kumthekar, G. V., Chakravarthi, R. M., Jonny, J., Gafor, A. H. A., et al. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-08008-7 · Cited by 11
Effects of Dapagliflozin on Health-Related Quality of Life in Patients with CKD
Bakker, W. M., Heerspink, H. J. L., Jongs, N., Correa‐Rotter, R., Rossing, P. R., Toto, R. D., Wheeler, D. C., McMurray, J. J. V., Langkilde, A. M., Gansevoort, R. T., et al. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000776 · Cited by 9
Kidney benefits of SLGT2 inhibitors: evidence from clinical trials
Wang, M. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00659-9 · Cited by 7
Sridhar, V. S., Neuen, B. L., Fletcher, R. A., Slee, A. E., Ang, F. G., Rapattoni, W., Arnott, C. G., Cherney, D. Z. I., Perkovic, V., Wheeler, D. C., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15112 · Cited by 11
“come of CV death or kidney disease progression studied in EMPAKIDNEY, there was some evidence that the magnitude of benefit increased with rising albuminuria.(7) One important caveat is that the present analysis was performed entirely in participants with T2D F IGURE 3 Change in eGFR over time (A) in the whole cohort…”
BackgroundResultInfluentialRastogi, A., & Weir, M. R. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108515 · Cited by 8
Vascular regenerative cells in cardiometabolic disease
Bakbak, E., Krishnaraj, A., Park, B., Verma, S., & Hess, D. A. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001089 · Cited by 9
Role of Semaphorin 3A in Kidney Development and Diseases
Sang, Y., Tsuji, K., Nakanoh, H., Fukushima, K., Kitamura, S., & Wada, J. (2023) · Diagnostics · doi:10.3390/diagnostics13193038 · Cited by 7
“One of the important advents for CKD therapy has been the use of sodium–glucose co-transporter-2 (SGLT-2) inhibitor [30,31], which slows down CKD progression.”
BackgroundEfficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c
Aggarwal, R., Bhatt, D. L., Szarek, M. J., Cannon, C. P., McGuire, D. K., Inzucchi, S. E., Lópes, R. D., Davies, M. J., Banks, P. L., Pitt, B., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.08.050 · Cited by 7
Schork, A., Eberbach, M.-L., Artunç, F., Bohnert, B. N., Eisinger, F., Heister, D. J., Vosseler, D., Nadalin, S., Birkenfeld, A. L., Heyne, N., et al. (2024) · Transplant International · doi:10.3389/ti.2024.12879 · Cited by 8
Wang, D., Mo, Y., Tan, X., Xie, J.-Y., Wang, H., & Wen, F. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02289-y · Cited by 7
Iordan, L., Lazăr, S., Timar, R. Z., Popescu, S. D., Sorescu, T., Albai, O., Braha, A., Timar, B., & Gaiţă, L. (2025) · Medicina · doi:10.3390/medicina61020209 · Cited by 10
“…circumference (WC), body mass index (BMI), subcutaneous fat area and visceral fat area, with improved insulin sensitivity, lower values of fasting insulin, reduction in hepatic steatosis and quantitative and qualitative improvements of LDL and high-density lipoprotein (HDL) particles [10,14,33–39].”
Hu, H., Liu, M., Fu, Z., Li, S., Wang, K., & Huang, Z. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-00861-y · Cited by 8
Schaub, J. A., Oerline, M., Crivelli, J. J., Maalouf, N. M., Best, S. L., Asplin, J. R., Hollingsworth, J. M., Shahinian, V. B., & Hsi, R. S. (2025) · Kidney360 · doi:10.34067/kid.0000000728 · Cited by 10
Sodium-glucose cotransporter 2 (SGLT2) inhibition and autoimmunity
Kronbichler, A. (2025) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2025.152663 · Cited by 6
Boonpiraks, K., Krisanapan, P., Anumas, S., Thongprayoon, C., Cheungpasitporn, W., & Pattharanitima, P. (2025) · F1000Research · doi:10.12688/f1000research.162502.1 · Cited by 8
Microalbuminuria as a Prognostic Marker in Essential Hypertension
Dimitriadis, K. S., Pyrpyris, N., Vakka, A., Iliakis, P., Theofilis, P., Tatakis, F., Beneki, E., Pitsiori, D., Tsioufis, P., Aznaouridis, K. A., et al. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673348953250310044927 · Cited by 11
Guo, G., Ke, M., Xu, J., Wu, W., Chen, J., Ke, C., Huang, P., & Lin, C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1520268 · Cited by 9
Diagnostic value of NLR, PLR and SIRI in peritoneal dialysis-associated peritonitis
Liu, Y. F. (2025) · American Journal of Translational Research · doi:10.62347/eqgn8207 · Cited by 6
Xu, J., Sun, A., Yang, Y., Shi, Y., Su, J., Eadon, M. T., & Zhang, P. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000687 · Cited by 9
Yang, Q., Wang, C., Wang, W., Li, Y., & Dang, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1585491 · Cited by 7
Wang, Y., Wang, Y., He, X., & Li, X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1554637 · Cited by 18
Peng, L., He, Y., Zhang, Z., Yin, J., & Fan, J. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2514078 · Cited by 6
“For example, It is effective in reducing hospitalization rates for HF, CVM, chronic kidney disease [21], and high-risk cardiovascular diseases [22].”
Yen, F., Huang, J., Dong, C., Hwu, C., Hsu, C., & Wei, J. C.-C. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112357 · Cited by 7
SGLT2 inhibitors in autoimmune diseases: emerging therapeutic potential and clinical challenges
Luo, T., Zhang, L., Tu, K., Li, G. L., Su, H., Gong, G., Huang, Y., Li, M., & Yang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1589341 · Cited by 9
Rico-Fontalvo, J. E., Ciudin, A., Correa‐Rotter, R., Diaz-Crespo, F. J., Bonanno, C., Lecube, A., Daza-Arnedo, R., Morales, E., Quiroga, B., Lorca, E., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.06.013 · Cited by 11
GLP1-RA and SGLT2-i: Implementation and Insulin Deescalation Strategies
Palani, A., Patel, S., Patel, S., Srivastava, S., Patel, J., Salehin, S., Birnbaum, Y., & Allencherril, J. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07744-8 · Cited by 8
“Of note, there was also an increased rate of amputation noted for unknown mechanisms [23].”
Wright, E. E., Cuenca, A. M. C., & Ngui, D. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.05.005 · Cited by 6
Effect of sodium-glucose cotransporter-2 inhibitors on skeletal muscle
Stöllberger, C., Finsterer, J., & Schneider, B. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.07.016 · Cited by 9
Yamao, Y., Ota, M., & Kanasaki, K. (2025) · Diabetology International · doi:10.1007/s13340-025-00839-5 · Cited by 7
“This hypothesis was subsequently validated by the CREDENCE [6], DAPA-CKD [7], and EMPA-KIDNEY [8] trials.”
Dhont, S., Singh, A., Swinnen, B., Vandebergen, K., Smolders, V., Meekers, E. M., Müllens, W., Martens, P., & Bertrand, P. B. (2025) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2025.2538386 · Cited by 6
“On the contrary, long-term data from EMPA-KIDNEY and other trials have confirmed the renoprotective properties of SGLT2i across various eGFR strata, likely mediated by sustained reductions in hyperfiltration, inflammation, and fibrosis [13].”
Lin, L., Shen, Z., Chen, Z. H., Yang, L., Su, Y., Teng, J., Ding, X., & Zhu, J. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70078 · Cited by 8
Pharmacologic Therapies for Type 2 Diabetes
Kuo, B., & Li, J. H. (2025) · NEJM Evidence · doi:10.1056/evidra2400265 · Cited by 9
“36 .”
Al-Azzawy, S. M., Coyle, M., Backer, G. D., McEvoy, J. W., Jennings, C. S., Kotseva, K., Mellbin, L., Rydén, L., Wood, D., Bacquer, D. D., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf528 · Cited by 9
Lan, N. S. R., McFadden, B., Johnson, A. R., Shedden, P., Fegan, P. G., Puttagunta, H., Ho, S., Gillett, R., Swaminathan, R., & Dwivedi, G. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.07.007 · Cited by 8
Luedde, M., Agewall, S., Ambrosio, G., Bayés‐Genís, A., Borghi, C., Cerbai, E., Dan, G. A., Drexel, H., Ferdinándy, P., Grove, E. L., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70069 · Cited by 11
Grilo, R. M., & Falcão, L. M. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.10.013 · Cited by 9
Ichijo, K., Yamaguchi, R., Takashima, H., Kobayashi, H. H., Maruyama, T., & Abe, M. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf292 · Cited by 8
Delanaye, P., Vart, P., Floege, J., & Zoccali, C. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf328 · Cited by 6
Lin, R., Hsu, C., Shih, M., Chien, K., & Wu, H. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70224 · Cited by 13
“Our findings have direct clinical relevance for the management of patients with T2DM and CKD. 12 Notably, dapagliflozin showed the greatest effect on composite renal outcomes, whereas canagliflozin demonstrated stronger reductions in albuminuria, suggesting that patient characteristics, such as…”
InfluentialAntoun, M. T. B., Borghol, A. H., Souvalian, L., Hadla, M., Abboud, G., Ghanem, A., Debeh, F. G. M., Mardirossian, J. M., Salih, M., Garimella, P. S., et al. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000943 · Cited by 11
Tseng, P., Zeng, B., Hsu, C.-W., Sun, C., Suen, M., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01750-x · Cited by 9
Next-Generation SGLT2 Inhibitors: Innovations and Clinical Perspectives
Man, D. E., Duda-Seiman, D. M., & Dragan, S. R. (2025) · Biomedicines · doi:10.3390/biomedicines14010081 · Cited by 11
Chiang, Y., Dai, D., Chiu, Y., & Lin, H. Y. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101248 · Cited by 9
de Moraes, T. P., Moura, A. F., Sposito, A. C., Lopes, F. P. P. L., QUADROS, A. R. D. A., Gadelha, V., Eliaschewitz, F. G., Bertoluci, M. C., Samaan, F., Montenegro, C., et al. (2026) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2025-0231en · Cited by 8
“…therapy (GDMT), once limited to pharmacological blockade of the renin-angiotensin-aldosterone system 1 , have expanded to include sodium-glucose cotransporter (SGLT2) inhibitors 2–4 , nonsteroidal mineralocorticoid receptor antagonists 5 , and glucagon-like peptide-1 (GLP-1) receptor agonists 6 .”
Heart Failure With Mildly Reduced Ejection Fraction
Wu, L., Rizwan, A. M., Rodriguez, M., Hachem, K. E., Virk, H. U. H., Khawaja, M., Strauß, M., & Krittanawong, C. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102476 · Cited by 13
Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities
Evans, P. C., Vilahur, G., Kleinbongard, P., Osto, E., Remme, C. A., Madonna, R., Aksentijević, D., Sourij, H., Davidson, S. M., Santovito, D., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag116 · Cited by 10
Kang, A., Smyth, B. J., Neuen, B. L., Heerspink, H. J. L., Tanna, G. L. D., Zhang, H., Arnott, C. G., Hockham, C., Agarwal, R., Bakris, G. L., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15091 · Cited by 6
Understanding Similarities and Differences in CKD and Dialysis Care in Children and Adults
Abderraman, G. M., Niang, A., Mohamed, T. H., Mahan, J. D., & Luyckx, V. A. (2023) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2023.151440 · Cited by 8
Lentine, K. L., Miyata, K. N., Lam, N. N., Joseph, C., McAdams‐DeMarco, M., Bae, S., Chen, Y., Çalışkan, Y., Sarabu, N., Dhindsa, S., et al. (2024) · Clinical Transplantation · doi:10.1111/ctr.15257 · Cited by 6
Wang, Y., Jiang, C., Dong, X., Chen, M., Gu, Q., Zhang, L., Fu, Y., Pan, T., Bi, Y., Song, W., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15596 · Cited by 7
Rikin, S., Bauman, L. J., Arnaoudova, I., Palo, K. E. D., Suda, N., Gupta, S., Deng, Y., & Golestaneh, L. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004155 · Cited by 8
Vitamin D: A Bridge between Kidney and Heart
Secondulfo, C., Visco, V., Virtuoso, N., Fortunato, M., Migliarino, S., Rispoli, A., Mura, L. L., Stellato, A., Caliendo, G., Settembre, E., et al. (2024) · Life · doi:10.3390/life14050617 · Cited by 10
Banjar, S., Alharbi, S., Omer, I., Zaid, N. A., Alghamdi, A., Abuthiyab, N., & Alzahrani, A. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132239 · Cited by 7
Immunosuppressive therapy for IgA nephropathy in children
Alladin, A., Hahn, D., Hodson, E. M., Ravani, P., Pfister, K., Quinn, R. R., & Samuel, S. M. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015060.pub2 · Cited by 8
SGLT-2 inhibitors: new horizons for rheumatologists
Chakrabarti, K., & McCune, W. J. (2024) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000001030 · Cited by 10
Conlin, P. R., Burke, B. V., Hobbs, C., Hurren, K. M., Lang, A. E., Morrison, J. W., Spacek, L., Steil, E. N., Watts, S. A., Weinreb, J. E., et al. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.04.014 · Cited by 8
Wallbach, M., Ajrab, J., Bayram, B., Pieper, D., Schäfer, A.-K. C., Lüders, S., Delistefani, F., Müller, D., & Koziolek, M. J. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae234 · Cited by 8
“The reduction in various endpoints, including the reduction in hospitalization for HF, observed in large clinical trials of SGLT2i is clear and impressive [12 –16 ].”
BackgroundUpadhyay, A., & Haider, L. (2024) · Clinical Diabetes · doi:10.2337/cd24-0036 · Cited by 6
Holt, S. G., Koornneef, E. J., Obaidli, A. A. K. A., Hubbert, L., & Nicholson, L. K. (2024) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s481121 · Cited by 6
Biomarker Panels for Predicting Progression of Kidney Disease in Acute Kidney Injury Survivors
Menez, S. P., Kerr, K. F., Cheng, S., Hu, D. G., Thiessen‐Philbrook, H., Moledina, D. G., Mansour, S. G., Go, A. S., Ikizler, T. A., Kaufman, J. S., et al. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000622 · Cited by 10
Zhang, Z., Tang, S., Liu, S., Leng, Y., Fu, X., Xie, H., Gao, H., & Xie, C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1408546 · Cited by 6
Chen, C., Huang, S., Ou, S., Ho, Y., Chen, T., Lee, K., Chu, Y.-C., Lin, Y.-P., Tseng, W., & Tarng, D. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.08.028 · Cited by 8
Use of SGLT2i in Non-Diabetic Kidney Transplant Recipients
Quilis, A., Gavela, E., Kanter, J., et al. (2025) · Transplantation Proceedings · doi:10.1016/j.transproceed.2024.12.009 · Cited by 6
Zhu, D., Judge, P. K., Staplin, N., Haynes, R., & Herrington, W. G. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae210 · Cited by 7
Vozza, A., Volpe, S., Custodero, C., Colaianni, V., Lavarra, V., Triggiani, D., Crudele, L., Bergamasco, A., Antonica, G., Tortorella, C., et al. (2025) · Journal of Diabetes Research · doi:10.1155/jdr/8182211 · Cited by 9
Sealey, J. E., & Blumenfeld, J. D. (2025) · Journal of Hypertension · doi:10.1097/hjh.0000000000003964 · Cited by 8
Montero, N., Oliveras, L., Martínez‐Castelao, A., Górriz, J. L., Soler, M. J., Fernández‐Fernández, B., Quero, M., García-Carro, C., García-Sancho, P., Goicoechea, M., et al. (2025) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2025.04.005 · Cited by 18
Guo, R., Pandey, A., Chandramouli, C., Wu, M., Cai, A., Liu, Y., Ren, Q. W., Huang, J., Zhang, J.-R., Gu, W., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16509 · Cited by 5
“19 However, individuals with high HbA1c variability are commonly excluded from RCTs due to not meeting the stringent inclusion criteria, thereby limiting the comprehensive understanding of the effects of SGLT2 inhibitors on this vulnerable patient subgroup.”
Lee, S. E., Yoo, J., Kim, B., Choi, H. S., Han, K., & Kim, K. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01006-z · Cited by 9
“This unique group needs further clarification of its pathophysiology, and therapeutic targets since recent EMPA-KIDNEY outcomes also showed no benefit of adding sodium-glucose cotransporter 2 (SGLT2) inhibitors in this group [34].”
BackgroundLin, C.-W., Hung, S., & Chen, I. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01059-0 · Cited by 7
Weaning Maintenance Therapy in Lupus Nephritis: For Whom, When, and How?
Jourde‐Chiche, N., Bobot, M., Burtey, S., Chiche, L., & Daugas, É. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.05.012 · Cited by 7
Immunglobulin-A-Vaskulitis (IgAV)
Rose, K., Turner, J., & Iking‐Konert, C. (2023) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-023-01355-0 · Cited by 8
Ghosal, S., & Sinha, B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1168755 · Cited by 7
“Primary endpoint CV death status EMPA KIDNEY (10) 2022 Empagliflozin 1,525/1,515 63.9 ± 13.9 2.0 26.1/73.9 NR Kidney disease progression or cardiovascular death Other secondary outcomes EMPAREG (5) 2015 Empagliflozin 4,645/2,323 63.0 ± 8.6) 3.1 99.5/0.5 9.9 3-”
InfluentialEffect of sotagliflozin on albuminuria in patients with type 2 diabetes and chronic kidney disease
Cherney, D. Z. I., Bhatt, D. L., Szarek, M. J., Sun, F., Girard, M., Davies, M. J., Pitt, B., Steg, P. G., & for the SCORED Investigators (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15203 · Cited by 8
Rossing, P. R., Groehl, F., Mernagh, P., Folkerts, K., Garreta-Rufas, A., Harris, J., Meredith, K., Carter, M., Åkerborg, Ö., Wanner, C., et al. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2235922 · Cited by 11
“Emerging therapies are improving physicians ’ ability to effectively manage CKD and prevent progression; therefore, it is increasingly important to identify patients early in the course of disease so that treatment can be initiated 5 – 8 .”
BackgroundTziastoudi, M., Chronopoulou, I., Pissas, G., Cholevas, C., Eleftheriadis, T., & Stefanidis, I. (2023) · Genes · doi:10.3390/genes14071488 · Cited by 7
Song, J., Li, X., & Ni, J. (2023) · Kidney & Blood Pressure Research · doi:10.1159/000534174 · Cited by 8
Merker, L., Ebert, T., Schleicher, E. D., Guthoff, M., & Isermann, B. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2076-0202 · Cited by 6
Garofalo, C., Borrelli, S., Liberti, M. E., Chiodini, P., Peccarino, L., Pennino, L., Polese, L., Gregorio, I. D., Scognamiglio, M., Ruotolo, C., et al. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.09.014 · Cited by 11
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group
- Corresponding author
- The EMPA-KIDNEY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-12
- Volume
- 388
- Issue
- 2
- Pages
- 117-127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7614055
- OpenAlex
- W4308183941
- Cited by
- 2,754
- References
- 26
- Citations by year
- 2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
- FWCI
- 321.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
- Hispana (submittedVersion, cc-by-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- NIHR Biomedical Centre, Oxford
- Health Data Research
- Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
- Kidney Research UK (MR/R007764/1)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.